中毒性表皮坏死松解
甲氨蝶呤
医学
速尿
药物警戒
背景(考古学)
药物不良反应
优势比
药物不良事件
皮肤病科
不利影响
药理学
药品
内科学
古生物学
生物
作者
Shengnan Zhuo,Yinghui Dong,Zhongsheng Yue,Yanyan Qian,Xinling Liu,Wei Liu
标识
DOI:10.1080/14740338.2023.2203482
摘要
Background Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare and life-threatening skin adverse reactions that are usually induced by drugs. This study aimed to assess the association between methotrexate and SJS/TEN when combined with furosemide.Research design and methods Data on suspicious, interactions (PS, SS, I) from the FDA Adverse Event Reporting System database for 2016–2021 were analyzed using the reporting odds ratio (ROR), information component (IC), proportional reporting ratio (PRR) and the Medications and Health Care Products Regulatory Agency (MHRA).Results We identified 28 case reports of TEN associated with the combination of furosemide and methotrexate and 10 reports of SJS associated with furosemide and methotrexate. The association of methotrexate with SJS/TEN was more significant in the entire data set when combined with furosemide than when methotrexate was not combined with furosemide. The association of methotrexate with SJS/TEN remained significant when furosemide was combined with methotrexate in a tumor-based disease context. After sensitivity analysis of the entire dataset as well as all antineoplastic drug datasets, consistent results were observed for TEN.Conclusions Our study confirmed a significant association between methotrexate and SJS/TEN when combined with furosemide, with an increased risk of SJS/TEN.
科研通智能强力驱动
Strongly Powered by AbleSci AI